Delivery Order SPE2DB22D3401-SPE2DB25FT5BN

Award Date 7/10/25
Potential Completion Date 7/11/25
Potential Value $7.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $7,589.49 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a medication, with a period of performance through May 20, 2025. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
This is a $15,299.21 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for 4568296791 ELIQUIS 5 MG TABLET 60S, with a completion date of May 20, 2025. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, providing a comprehensive global pharmaceutical support vehicle through December...
This is a $65,131.20 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has an ultimate completion date of July 14, 2025. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle for the DLA, Defense...
This is a $16,267.24 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 5 MG TABLET 60S. The contract has an ultimate completion date of May 16, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support...
This is a $6,876.57 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a period of performance through March 4, 2024. The contract is not set aside for any specific business category. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC)...
This is a $11,291.46 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ELIQUIS 5 MG TABLET 60S, a medication, and does not have a set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This is a $6,334.92 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ELIQUIS 2.5 MG TABLET 60S. The contract is a firm fixed-price, non-set-aside award with a completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support...
This is a $6,627.68 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a prescription medication, with a performance period ending on July 10, 2025. The contract is not set aside and was awarded on July 9, 2025. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a firm fixed price of $12,655.27 and a completion date of June 10, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $35,139.24, is for the delivery of ELIQUIS 5 MG TABLET 60S, a prescription medication, with a period of performance through June 4, 2025. The contract is not set aside and was awarded on an unrestricted basis. AmerisourceBergen Drug Corp holds a significant $999,999,999.00...
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT5BN
    Delivery Order

This is a $7,301.27 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, with a performance period ending on July 11, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is not designated as a set-aside contract.

Generated 10/12/25, 12:45 AM